email article That s a demand that utterly outstrips the supply that we have. Jim Jackson, PsyD, of Vanderbilt University Medical Center in Nashville, on a study suggesting that many COVID survivors have post-traumatic stress disorder. It s like taking a football and shoving it into a pipe with the diameter of a golf ball. David Nauen, MD, PhD, of Johns Hopkins University in Baltimore, about the unexpected presence of megakaryocytes in the brain capillaries of people who died with COVID-19. This is one of those findings where you can hear it at [the Genitourinary Cancers Symposium] and take it to the clinic on Monday. Sumanta Pal, MD, of City of Hope Comprehensive Cancer Center in Duarte, California, discussing a new option for a rare type of kidney cancer.
email article
Patients with progressive mesothelioma obtained a first-ever survival improvement with nivolumab (Opdivo) as second-line therapy, a randomized trial showed.
Median overall survival (OS) increased by almost 40%, and the progression-free interval also improved significantly with the immune checkpoint inhibitor as compared with placebo. In particular, a significant clinical benefit was evidence in patients with epithelioid subtype, the predominant mesothelioma histology.
PD-L1 expression status did not influence response to treatment, although only a third of patients tested positive for the biomarker, reported Dean Fennell, MD, of the University of Leicester in England, at the virtual World Conference on Lung Cancer.